Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-04

AUTHORS

M. Inouye, T. Mio, K. Sumino

ABSTRACT

Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35–72 years, mean ± SD=55.3 ± 13.8 years) and fifteen hypertensive patients (seven females and eight males aged 45–80 years, mean ± SD = 60.2 ± 11.8 years) were recruited. Patients were treated orally with nilvadipine (4 mg b.i.d.) for 4 weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4 weeks after nilvadipine treatment and in healthy subjects were 6.5 ± 1.6% (mean ± SD), 3.8 ± 1.2%, and 0.2 ± 0.1%, respectively. There were significantly (P < 0.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P < 0.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis. More... »

PAGES

35-41

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050717

DOI

http://dx.doi.org/10.1007/s002280050717

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046077486

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10853875


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arteriosclerosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nifedipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxidative Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP", 
          "id": "http://www.grid.ac/institutes/grid.413722.1", 
          "name": [
            "Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inouye", 
        "givenName": "M.", 
        "id": "sg:person.01052526706.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052526706.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.31432.37", 
          "name": [
            "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mio", 
        "givenName": "T.", 
        "id": "sg:person.01303203706.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303203706.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.31432.37", 
          "name": [
            "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sumino", 
        "givenName": "K.", 
        "id": "sg:person.0625412514.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625412514.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02940252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051361641", 
          "https://doi.org/10.1007/bf02940252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00051106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047626214", 
          "https://doi.org/10.1007/bf00051106"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-04", 
    "datePublishedReg": "2000-04-01", 
    "description": "Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35\u201372\u2009years, mean\u2009\u00b1\u2009SD=55.3\u2009\u00b1 13.8\u2009years) and fifteen hypertensive patients (seven females and eight males aged 45\u201380\u2009years, mean\u2009\u00b1 SD\u2009= 60.2\u2009\u00b1\u200911.8\u2009years) were recruited. Patients were treated orally with nilvadipine (4\u2009mg b.i.d.) for 4\u2009weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4\u2009weeks after nilvadipine treatment and in healthy subjects were 6.5\u2009\u00b1\u20091.6% (mean\u2009\u00b1\u2009SD), 3.8\u2009\u00b1\u20091.2%, and 0.2\u2009\u00b1 0.1%, respectively. There were significantly (P\u2009<\u20090.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P\u2009<\u20090.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050717", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "56"
      }
    ], 
    "keywords": [
      "low-density lipoprotein", 
      "hypertensive patients", 
      "nilvadipine treatment", 
      "healthy subjects", 
      "risk factors", 
      "high risk", 
      "low-density lipoprotein cholesterol", 
      "antioxidant effects", 
      "vivo oxidation", 
      "oxidation of LDL", 
      "lipoprotein cholesterol", 
      "LDL cholesterol", 
      "calcium antagonists", 
      "patients", 
      "atherosclerosis", 
      "nilvadipine", 
      "lipid peroxidation", 
      "cholesterol", 
      "cholesterol oxidation", 
      "available markers", 
      "treatment", 
      "subjects", 
      "weeks", 
      "risk", 
      "hypertension", 
      "therapy", 
      "antagonist", 
      "levels", 
      "lipoproteins", 
      "antioxidant activity", 
      "factors", 
      "peroxidation", 
      "effect", 
      "vivo", 
      "markers", 
      "aim", 
      "agents", 
      "ratio", 
      "activity", 
      "study", 
      "data", 
      "oxidation level", 
      "oxidation", 
      "cholestadien", 
      "Cholesterol oxidation levels", 
      "nilvadipine therapy"
    ], 
    "name": "Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis", 
    "pagination": "35-41", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046077486"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050717"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10853875"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050717", 
      "https://app.dimensions.ai/details/publication/pub.1046077486"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_332.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050717"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      22 PREDICATES      91 URIs      80 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050717 schema:about N064350eb59ee43889d997dd64b7c8f91
2 N0f5c63110d5b4a2d92073e0aa7620308
3 N2e5c0fe2523541d8b9eae2332fb06286
4 N2ff3f13663064b9caaf1297dd6ae6a11
5 N4eeb6ce183b84cc197fcf53883dc72cf
6 N5330d1e9717b43ba9e99eefd78ba70da
7 N64c9d0f9318f4338ad673c997739f6a3
8 N6e17ce4191e04e4e9d5e88866c4cb091
9 N73fc2ae7ba964ac5a0247a90c9bf5b50
10 N86c902bcd88a4b28ba4674cbaa408dfb
11 N9402909bab7d42f39f65141541d8bd78
12 Nd5769f37d034461e9ac1f34b05096ae7
13 Ne71bc3e7fa8b41b7af6c45d80b82b062
14 Ne964a61fd5b044a09df82cc8418f9278
15 Nfc941fe72dfb408090001fb99fa74dae
16 anzsrc-for:11
17 anzsrc-for:1102
18 anzsrc-for:1103
19 schema:author N0d9767ee8a6b4fa586a82749990fe1e7
20 schema:citation sg:pub.10.1007/bf00051106
21 sg:pub.10.1007/bf02940252
22 schema:datePublished 2000-04
23 schema:datePublishedReg 2000-04-01
24 schema:description Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35–72 years, mean ± SD=55.3 ± 13.8 years) and fifteen hypertensive patients (seven females and eight males aged 45–80 years, mean ± SD = 60.2 ± 11.8 years) were recruited. Patients were treated orally with nilvadipine (4 mg b.i.d.) for 4 weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4 weeks after nilvadipine treatment and in healthy subjects were 6.5 ± 1.6% (mean ± SD), 3.8 ± 1.2%, and 0.2 ± 0.1%, respectively. There were significantly (P < 0.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P < 0.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N5bc785c178d94b32a1988ad963a37db2
29 N6bf86fabedb541d8b8a0137dd1e109c3
30 sg:journal.1054337
31 schema:keywords Cholesterol oxidation levels
32 LDL cholesterol
33 activity
34 agents
35 aim
36 antagonist
37 antioxidant activity
38 antioxidant effects
39 atherosclerosis
40 available markers
41 calcium antagonists
42 cholestadien
43 cholesterol
44 cholesterol oxidation
45 data
46 effect
47 factors
48 healthy subjects
49 high risk
50 hypertension
51 hypertensive patients
52 levels
53 lipid peroxidation
54 lipoprotein cholesterol
55 lipoproteins
56 low-density lipoprotein
57 low-density lipoprotein cholesterol
58 markers
59 nilvadipine
60 nilvadipine therapy
61 nilvadipine treatment
62 oxidation
63 oxidation level
64 oxidation of LDL
65 patients
66 peroxidation
67 ratio
68 risk
69 risk factors
70 study
71 subjects
72 therapy
73 treatment
74 vivo
75 vivo oxidation
76 weeks
77 schema:name Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis
78 schema:pagination 35-41
79 schema:productId N1c20271faa1744b5aae7c6af07edd360
80 Nbd98ab2da84f415e8ac326e9ff013554
81 Nc60431aabb1941489cc32000e41a08bb
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046077486
83 https://doi.org/10.1007/s002280050717
84 schema:sdDatePublished 2021-12-01T19:13
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Ne8a75c98e7fa444fb571d528034e9260
87 schema:url https://doi.org/10.1007/s002280050717
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N064350eb59ee43889d997dd64b7c8f91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Hypertension
93 rdf:type schema:DefinedTerm
94 N0d9767ee8a6b4fa586a82749990fe1e7 rdf:first sg:person.01052526706.24
95 rdf:rest N86a420036c8249d79fc04b18611ee8ab
96 N0f5c63110d5b4a2d92073e0aa7620308 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Adult
98 rdf:type schema:DefinedTerm
99 N1c20271faa1744b5aae7c6af07edd360 schema:name doi
100 schema:value 10.1007/s002280050717
101 rdf:type schema:PropertyValue
102 N2e5c0fe2523541d8b9eae2332fb06286 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Case-Control Studies
104 rdf:type schema:DefinedTerm
105 N2ff3f13663064b9caaf1297dd6ae6a11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Middle Aged
107 rdf:type schema:DefinedTerm
108 N4eeb6ce183b84cc197fcf53883dc72cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Arteriosclerosis
110 rdf:type schema:DefinedTerm
111 N5330d1e9717b43ba9e99eefd78ba70da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Risk Factors
113 rdf:type schema:DefinedTerm
114 N5bc785c178d94b32a1988ad963a37db2 schema:volumeNumber 56
115 rdf:type schema:PublicationVolume
116 N64a282cbb04e4806aa6b899607a462b5 rdf:first sg:person.0625412514.00
117 rdf:rest rdf:nil
118 N64c9d0f9318f4338ad673c997739f6a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Cholesterol, LDL
120 rdf:type schema:DefinedTerm
121 N6bf86fabedb541d8b8a0137dd1e109c3 schema:issueNumber 1
122 rdf:type schema:PublicationIssue
123 N6e17ce4191e04e4e9d5e88866c4cb091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 N73fc2ae7ba964ac5a0247a90c9bf5b50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Aged, 80 and over
128 rdf:type schema:DefinedTerm
129 N86a420036c8249d79fc04b18611ee8ab rdf:first sg:person.01303203706.66
130 rdf:rest N64a282cbb04e4806aa6b899607a462b5
131 N86c902bcd88a4b28ba4674cbaa408dfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 N9402909bab7d42f39f65141541d8bd78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Antihypertensive Agents
136 rdf:type schema:DefinedTerm
137 Nbd98ab2da84f415e8ac326e9ff013554 schema:name dimensions_id
138 schema:value pub.1046077486
139 rdf:type schema:PropertyValue
140 Nc60431aabb1941489cc32000e41a08bb schema:name pubmed_id
141 schema:value 10853875
142 rdf:type schema:PropertyValue
143 Nd5769f37d034461e9ac1f34b05096ae7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 Ne71bc3e7fa8b41b7af6c45d80b82b062 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Nifedipine
148 rdf:type schema:DefinedTerm
149 Ne8a75c98e7fa444fb571d528034e9260 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 Ne964a61fd5b044a09df82cc8418f9278 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged
153 rdf:type schema:DefinedTerm
154 Nfc941fe72dfb408090001fb99fa74dae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Oxidative Stress
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
161 schema:name Cardiorespiratory Medicine and Haematology
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
164 schema:name Clinical Sciences
165 rdf:type schema:DefinedTerm
166 sg:journal.1054337 schema:issn 0031-6970
167 1432-1041
168 schema:name European Journal of Clinical Pharmacology
169 schema:publisher Springer Nature
170 rdf:type schema:Periodical
171 sg:person.01052526706.24 schema:affiliation grid-institutes:grid.413722.1
172 schema:familyName Inouye
173 schema:givenName M.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052526706.24
175 rdf:type schema:Person
176 sg:person.01303203706.66 schema:affiliation grid-institutes:grid.31432.37
177 schema:familyName Mio
178 schema:givenName T.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303203706.66
180 rdf:type schema:Person
181 sg:person.0625412514.00 schema:affiliation grid-institutes:grid.31432.37
182 schema:familyName Sumino
183 schema:givenName K.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625412514.00
185 rdf:type schema:Person
186 sg:pub.10.1007/bf00051106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047626214
187 https://doi.org/10.1007/bf00051106
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/bf02940252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051361641
190 https://doi.org/10.1007/bf02940252
191 rdf:type schema:CreativeWork
192 grid-institutes:grid.31432.37 schema:alternateName Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP
193 schema:name Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP
194 rdf:type schema:Organization
195 grid-institutes:grid.413722.1 schema:alternateName Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP
196 schema:name Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...